

Ref: EPL/CS/SE/0091/2026**Date:** October 14, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation for Earnings Call – Q2 FY27

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that the **Earnings Call for Investors / Analysts** will be held on **Tuesday, November 03, 2026**, at **4.00 p.m. (IST)** to discuss the Company's Unaudited Financial Results (Standalone and Consolidated) and performance for the quarter and half-year ended September 30, 2026.

The details of the aforesaid earnings call for Investors/Analysts is enclosed.

The transcript and the audio recording of the Earnings Call will be made available on the Company's website i.e. www.emcure.com and will be intimated accordingly.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

AMRUTA
AMIT
YANGALWAR

Digitally signed
by AMRUTA AMIT
YANGALWAR
Date: 2026.10.14
15:55:28 +05'30'

Amruta Yangalwar
Company Secretary & Compliance Officer
ICSI Membership No.: A25687

Emcure Pharmaceuticals Limited**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Invitation for Earnings Call

The management team of Emcure Pharmaceuticals Limited will host a conference call for analysts and investors following the announcement of the Company's financial results for the quarter ended September 30, 2026.

The call will be conducted via Zoom Webinar and will begin with brief remarks from the management team, followed by a question-and-answer session.

Please use the registration link below to participate.

CONFERENCE CALL DETAILS

Date Tuesday, November 3, 2026

Time 04:00 pm IST

Registration [CLICK HERE TO REGISTER](#)

Audio Recording Will be made available before the next trading day or within 24 hours from the end of the call, whichever is earlier.

Recording Access Available on the Company website:
Emcure > Investors > Financial > Earnings Call Recordings

Conference Call Transcript Will be made available within 5 working days from the conclusion of the call.

Transcript Access Available on the Company website:
Emcure > Investors > Financial > Earnings Call Transcript

Note: Participants are requested to join 10 minutes before the scheduled start time of the call.

For further information / institutional investor queries
Saurabh Paliwal | investor.relations@emcure.com

DISCLAIMER

Certain statements made during the conference call, including during the question-and-answer session, may constitute forwardlooking statements based on the current expectations, assumptions and projections of Emcure Pharmaceuticals Limited. Such statements are not guarantees of future performance and are subject to risks and uncertainties, including regulatory, product development, approval, commercialization, intellectual-property, manufacturing, supply-chain, competitive, currency and market related factors—that could cause actual results to differ materially. Participants should not place undue reliance on these statements. The call is for general informational purposes only and does not constitute investment or medical advice, or an offer, solicitation or recommendation to buy, sell or subscribe to any securities of the Company. Information concerning products or indications under development or awaiting approval is subject to applicable regulatory requirements and intellectual-property rights, and availability may vary by jurisdiction. The Company undertakes no obligation to publicly update any forward-looking statement except as required under applicable law.